Correlation Between Quality of Life (QoL) of Patients Treated With Nivolumab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) and Their Caregivers
Author(s)
Baumstarck K1, Even C2, Grumberg V3, Schwartz D4, Lahaye J4, Pointreau Y5, Ceruse P6, Babin E7, Fayette J8, Rondeau V9, Cotte FE10, Govart A11, Salas S12, Le Tourneau C13
1Université Aix-Marseille, Marseille, France, 2Gustave Roussy, Villejuif, France, 3Paris Saclay University and Bristol Myers Squibb, PARIS 18, 75, France, 4Kappa Santé, Paris, France, 5Inter-regional Cancer Institute Jean Bernard Center, Le Mans, France, 6Lyon-Nord University Hospital, Lyon, France, 7Caen Normandie University Hospital, Caen, France, 8Leon Berard Center, Lyon, France, 9Bordeaux Population Health Center, ISPED, Centre INSERM U1219, Bordeaux, France, 10Bristol Myers Squibb, Rueil-Malmaison, Hauts-De-Seine, France, 11Bristol Myers Squibb, Rueil-Malmaison, France, 12AP-HM AMU Aix Marseille University, Marseille, France, 13Institut Curie, Paris, France
Presentation Documents
OBJECTIVES: ProNiHN is a prospective, observational, and multicenter study of patients with R/M SCCHN treated with nivolumab after progression or after platinum-based therapy. The objective was the evolution of, and correlation between, patient and caregiver QoL.
METHODS: QoL of patients was measured with 2 questionnaires (FACT-H&N and EQ-5D-3L) at baseline, 6 weeks, 3, 6, 12 and 18 months. QoL of caregivers was assessed with CarGOQoL questionnaire and their needs by the SCNS-P&C-F at baseline and 6 months. Correlation of questionnaires total scores and dimensions were assessed with Spearman correlation coefficients.
RESULTS: Overall, 487 patients were included. Among them, 354 completed at least one questionnaire at baseline. QoL data were assessed at baseline and 6-months for 121 patients for FACT H&N and 116 patients for EQ-5D-3L. 258 caregivers gave their consent to the study. Among them, 184 reported QoL data at baseline. CarGOQoL was completed at baseline and 6 months by 48 caregivers and SCNS-P&C-F by 44 caregivers.
Matched patients-FACT-H&N and caregivers-CarGOQoL results were weakly correlated at baseline (0.226, p<0.01) and moderately correlated at 6 months (0.362; p<0.01). In patients with caregivers and a stable or improved QoL (n=22), 68.2% of their caregivers had an improved or stable QoL. Of patients whose QoL had deteriorated at 6 months (n=25), 64.0% of their caregivers had a deteriorated QoL. Patients-FACT-H&N results were inversely weakly correlated with caregivers-SCNS-P&C-F at baseline (-0.170; p<0.05) and at 6 months (-0.281; p<0.05). Patients-EQ-5D-3L utility index scores and caregivers-CarGOQoL scores were weakly correlated at baseline (0.160, p<0.05) and moderately correlated at 6 months (0.489; p<0.001). EQ-VAS was not significantly correlated with caregiver QoL questionnaires at baseline. EQ-VAS was inversely correlated with SCNS P&C-F at 6 months (-0.413; p<0.01)CONCLUSIONS: In this study, QoL of caregivers and patients were weakly correlated at baseline, and tended to be moderately correlated at 6 months.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR132
Topic
Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods
Disease
Drugs, Oncology